Zobrazeno 1 - 10
of 64
pro vyhledávání: '"K Maman"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Value in Health. 25:S530
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e92737770b57fb07bc4480ae1228432
https://doi.org/10.1016/j.jval.2022.04.1268
https://doi.org/10.1016/j.jval.2022.04.1268
Autor:
Jameel Nazir, Richard Zur, Emad Siddiqui, K. Maman, Christopher R. Chapple, Samuel Aballéa, Con Kelleher, Zalmai Hakimi
Publikováno v:
European Urology. 74:324-333
Background Mirabegron is an established treatment alternative to antimuscarinic therapy for patients with overactive bladder (OAB), as shown by efficacy and tolerability data from phase III trials. Objective To assess efficacy and tolerability of mir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b07ec728bbf1ebb31ac99c270904fc7d
https://doi.org/10.1016/j.eururo.2018.03.020
https://doi.org/10.1016/j.eururo.2018.03.020
Autor:
Jameel Nazir, Con Kelleher, Isaac Odeyemi, Samuel Aballéa, K. Maman, Colette Mankowski, Zalmai Hakimi
Publikováno v:
Neurourology and Urodynamics. 37:986-996
Aims To compare efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents for the treatment of overactive bladder (OAB). Methods Literature searches of MEDLINE, Embase, and the Cochrane Library were undertaken to ident
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4b76ef5bc0bf7a5bbf92e4482292124
https://doi.org/10.1002/nau.23413
https://doi.org/10.1002/nau.23413
Autor:
Mohamed-Elmoctar Neine, Jameel Nazir, Isaac Odeyemi, Samuel Aballéa, K. Maman, Zalmai Hakimi, B. Briquet, Andy Garnham
Publikováno v:
Value in Health. 18:783-790
Background Mirabegron, a first-in-class selective oral β 3 -adrenoceptor agonist, has similar efficacy to most antimuscarinic agents and a lower incidence of dry mouth in patients with overactive bladder (OAB). Objectives To evaluate the cost-effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31e50b51cafe65742d60c731aea8282c
https://doi.org/10.1016/j.jval.2015.05.011
https://doi.org/10.1016/j.jval.2015.05.011
Autor:
Andy Garnham, K. Maman, Samuel Aballéa, Zalmai Hakimi, Isaac Odeyemi, Mondher Toumi, Jameel Nazir, K. Thokagevistk
Publikováno v:
Clinical Drug Investigation
Background Overactive bladder (OAB) is highly prevalent and is associated with considerable morbidity and reduced health-related quality of life. β3-adrenergic receptor (β3-AR) stimulation is a novel alternative to antimuscarinic therapy for OAB. O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb15698e105f68bbcec37e24543f2d45
https://doi.org/10.1007/s40261-014-0240-z
https://doi.org/10.1007/s40261-014-0240-z
Autor:
Jameel Nazir, Samuel Aballéa, Emad Siddiqui, Isaac Odeyemi, Katia Desroziers, K. Maman, Zalmai Hakimi, Mohamed-Elmoctar Neine
Publikováno v:
European Urology. 65:755-765
Context Overactive bladder (OAB) treatment guidelines recommend antimuscarinics as first-line pharmacologic therapy. Mirabegron is a first-in-class β3-adrenoceptor agonist licensed for the treatment of OAB and has shown to be well tolerated and eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b59bdf0c4cefe6703a1a23f1629d4e6
https://doi.org/10.1016/j.eururo.2013.11.010
https://doi.org/10.1016/j.eururo.2013.11.010
Publikováno v:
Value in Health. 22:S226
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26797d331fdfbc610c970678fa5c04c8
https://doi.org/10.1016/j.jval.2019.04.1050
https://doi.org/10.1016/j.jval.2019.04.1050
Publikováno v:
Expert Opinion on Pharmacotherapy. 13:9-16
Prolonged-release (PR) melatonin is approved in Europe for the treatment of insomnia in patients aged 55 years and above. The objective of the study was to describe its prescription patterns and its impact on hypnotics use in routine clinical practic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c8566671927de4724d22f2c0b7e9816
https://doi.org/10.1517/14656566.2012.638284
https://doi.org/10.1517/14656566.2012.638284
Publikováno v:
Value in Health. 20:A804
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c00eee3faa29380de03d01241816c4b7
https://doi.org/10.1016/j.jval.2017.08.3068
https://doi.org/10.1016/j.jval.2017.08.3068